Frova

Citigroup has released its Endo Pharmaceuticals Holdings (NASDAQ: ENDP) core product trends for the week ending 10/15/2010. Lidoderm, Opana, and Frova are among the medications featured in the report. “We arrive at our $40 price target for Endo based on a relative 2011 P/E multiple compared to the...